Commercializationv1 · 09.29
What Does Chugai Still See in a Drug Roche Is Walking Away From? ↗
Which patients and product proposition could make a discontinued program viable?
As Roche exits all development, Chugai is reclaiming rights, preparing to resume SMA work and considering an outside licensing deal.
- Reports and agreements reviewedRecorded
- Further validationUnverified
- Adoption and benefitUnverified
New question opened
Recorded a new question and follow-up checks from the approved manuscript.
NEXT CHECK
Patient selection, functional endpoints, long-term evidence and licensing terms.